The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

The Journal of Immunology, 2008, 181, 6702 -6706
Copyright © 2008 by The American Association of Immunologists, Inc.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mossman, K. L.
Right arrow Articles by Ashkar, A. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mossman, K. L.
Right arrow Articles by Ashkar, A. A.

Cutting Edge: FimH Adhesin of Type 1 Fimbriae Is a Novel TLR4 Ligand1

Karen L. Mossman*, M. Firoz Mian*, Nicole M. Lauzon*, Carlton L. Gyles{dagger}, Brian Lichty*, Randy Mackenzie*, Navkiran Gill* and Ali A. Ashkar2,*

* Centre for Gene Therapeutics, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada; and {dagger} Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Several TLR ligands of bacterial origin induce innate immune responses. Although FimH, the adhesin portion of type 1 fimbria, plays an important role in the pathogenicity of some Gram-negative bacteria, its ability to stimulate the innate immune system via TLR signaling remains unclear. In this study we report that FimH induces potent innate responses in a MyD88-dependent fashion. The FimH-induced innate activity was restricted to cells expressing TLR4. In addition, FimH was able to bind directly to TLR4. More importantly, cells unresponsive to LPS were responsive to FimH and the presence or absence of MD-2 and CD14 had no effect on FimH activity. Our data suggest that TLR4 is a functional receptor for the adhesin portion of bacterial type 1 fimbria.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Bacteria encode numerous pathogen-associated molecular patterns (PAMPs),3 including LPS, flagellin, peptidoglycan and bacterial DNA, that can activate the innate immune system via TLRs (1, 2). Upon ligand binding, TLRs initiate signaling via interactions between their cytoplasmic Toll/IL-1R (TIR) domain and cellular adaptor molecules. These pathways can be divided into common (MyD88-dependent) and specific (MyD88-independent) categories. TLR2, 5, 7–9, and 11 signaling is MyD88-dependent, while TLR3 and 4 signaling is mediated through either MyD88 or Trif.

Enterobacteriaceae, including uropathogenic Escherichia coli (UPEC), encode fimbriae that mediate attachment to mucosal epithelial surfaces. Type I fimbriae have long been implicated in bacterial urinary tract infections in humans (3) and have been the focus of many attempts to generate a vaccine against pathogenic Gram-negative bacteria (4, 5). In vivo studies indicate that type 1 fimbriae play an important role in pathogenesis. Furthermore, E. coli expressing both P and type 1 fimbriae were found to activate TLR4 in mucosal tissues (6). FimH, the adhesin portion of type 1 fimbriae, is involved in bacterial attachment to epithelial cells through interactions with mannose (5, 7). Although the role of FimH in pathogenicity is well appreciated, there is no report of FimH inducing innate host responses. In this study, we provide evidence that purified FimH is a protein ligand for TLR4 and induces potent proinflammatory cytokine production through MyD88. Furthermore, we show that FimH activity is independent of LPS signaling and can occur in cells unresponsive to this ubiquitous bacterial PAMP.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Cells, viruses, and reagents

RAW264.7, human embryonic lung (HEL) fibroblasts, and BJ fibroblasts were purchased from American Type Culture Collection. C57BL/6 (B6) murine embryonic fibroblasts (MEFs) were grown in {alpha}-MEM with 10% FBS for experiments. 293, 293-human TLR4 (hTLR4), and 293-hTLR4-CD14/MD2 cells were purchased from InVivoGen and maintained in DMEM with 10% FBS and 10 µg/ml blasticidin (293-hTLR4) or 10 µg/ml blasticidin and 50 µg/ml HygroGold (293-hTLR4-CD14/MD2). Vesicular stomatitis virus (VSV)-GFP expresses GFP from the viral promoter. LPS (L26–54) and polyinosinic:polycytidylic acid (poly(I:C)) were purchased from Sigma-Aldrich.

Purification of FimH

The fimH gene from E. coli strain EC99 (O78) was cloned into pQE-30 and expressed in BL-21-competent E. coli. FimH expression and purification were performed as previously described (8). LPS levels in FimH preparations were determined using a Limulus amebocyte lysate LPS detection kit as directed.

ELISA

TNF-{alpha} and IL-8 ELISAs were conducted using Quantikine murine kits from R&D Systems according to the manufacturer’s instructions. An unpaired t test was used to determine significant differences in cytokine production.

Preparation of peritoneal macrophages

Peritoneal macrophages were prepared from B6, MyD88–/–, and TLR4–/– mice by injecting 6 ml of warm RPMI 1640 into the peritoneal cavity and collecting the fluid after 10 min. Peritoneal macrophages were seeded at 1 x 105 cells/well in a 96-well plate, incubated for 1 h, and then washed to remove nonadherent cells.

RT-PCR

RNA was harvested using TRIzol (Invitrogen) as directed. RT-PCR was performed as previously described (9) using the following primers: TLR4 forward and reverse, 5'-CTGGACCTCTCTCAGTGTC-3' and 5'-GGCAGAGCTGAAATGGAGG-3'; MD-2 forward and reverse, 5'-GAAGCTCAGAAGCAGTATTGGGTC-3' and 5'-GGTTGGTGTAGGATGACAAACTCC-3'; GAPDH forward and reverse, 5'-CGGAGTCAACGGATTTGGTCGTA-3' and 5'-AGCCTTCTCCATGGTGGTGAAGAC-3'.

Luciferase assays

293, 293-hTLR4, and 293-hTLR4-CD14-md2 cells seeded in 24-well dishes were cotransfected with pCMV-βgal (50 ng; Clontech) and pNF{kappa}B-luc (500 ng; Clontech). Sixteen hour later, cells were left untreated (control) or treated with FimH (2 µg/ml) or LPS (10 ng/ml). Six hours later, cells lysates were harvested and luciferase assays were performed as directed (BD Biosciences). β-Galactosidase activity was measured as an internal control as directed (BD Biosciences). Data were analyzed using GraphPad.

FimH-TLR4 interaction/binding assay

High-binding ELISA plates (Costar) were coated with increasing concentrations of FimH or LPS overnight at 4°C, and then blocked with 2% BSA in PBS for 1 h before incubation with 2 µg/ml human TLR4-Fc fusion protein. After three washes with PBS and Tween 20, the captured TLR4-Fc was detected using a HRP-conjugated goat anti-human IgG Ab (Bethyl Laboratories.). Binding of the immobilized FimH or LPS to another murine membrane protein, IL-15R{alpha}-Fc, was performed similarly as a negative control and to show specificity of interactions.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
FimH stimulation of macrophages is MyD88 dependent

Type 1 fimbriae, comprised of FimA, FimF, FimG, and FimH, stimulate the innate immune response (6), and FimH activates microglia to produce NO (10). To determine whether FimH alone can activate macrophages, we purified recombinant FimH (Fig. 1A) and tested the protein on RAW264.7 murine macrophages, which express all TLRs except TLR5. We measured production of TNF-{alpha} (Fig. 1B) and NO (Fig. 1C) in response to FimH and poly(I:C) treatment. FimH induced both TNF-{alpha} and NO. Because MyD88 null mice fail to clear P and type 1 fimbriated E. coli infection, we examined the role of MyD88 in FimH-mediated TNF-{alpha} and NO production. Peritoneal macrophages from MyD88–/– or B6 control mice were treated with FimH and the levels of TNF-{alpha} and NO were measured. MyD88–/– peritoneal macrophages were unresponsive to FimH, whereas B6 peritoneal macrophages induced significant amounts of TNF-{alpha} and NO (Fig. 1, D and E).


Figure 1
View larger version (23K):
[in this window]
[in a new window]

  		FIGURE 1. FimH-mediated induction of TNF-{alpha} and NO in macrophages is MyD88 dependent. A, SDS-PAGE of purified recombinant FimH stained with Coomassie blue. B and C, RAW264.7 cells were treated with FimH (10 µg/ml), poly(I:C) (10 µg/ml), or left untreated (control), and TNF-{alpha} and NO (Nitrite) were measured in supernatants. D and E, Peritoneal macrophages from B6 and MyD88–/– mice were treated with FimH, poly(I:C), or PBS (control) and TNF-{alpha} and NO (Nitrite) were measured.

 
FimH elicits an antiviral response in cells expressing TLR4

Because both P and type 1 fimbriae signal through TLR4 (6), we examined whether FimH alone possesses this activity. We used either cells from TLR4–/– mice or two nonimmortalized, nontransformed human fibroblast lines that either express TLR4 (BJ foreskin fibroblast) or do not (HEL lung fibroblast) (9). The rationale for using a human cell type devoid of TLR4 was that human cells do not express TLR11, a murine-specific TLR that recognizes PAMPs from FimH+ UPEC (11). In addition to cytokine secretion (Fig. 2A), an antiviral state assay using VSV-GFP was used (Fig. 2B) where an antiviral state capable of blocking VSV-GFP replication is indicated by the absence of GFP fluorescence. All cells tested responded to poly(I:C) (Fig. 2). However, peritoneal macrophages from TLR4–/– mice were unresponsive to both LPS and FimH (Fig. 2A). At concentrations of LPS ≥10 ng/ml, both BJ fibroblasts and B6 MEFs responded to LPS, confirming the presence of TLR4. In contrast, HEL fibroblasts failed to respond to LPS, even at 1000-fold higher concentrations (10). Similarly, whereas no antiviral activity was observed in HEL fibroblasts treated with FimH, FimH induced a complete antiviral response in both BJ fibroblasts and B6 MEFs (Fig. 2B). Complete abrogation of responsiveness to FimH was observed at 30 ng/ml and 10 ng/ml in B6 MEFs and BJ fibroblasts, respectively (data not shown).


Figure 2
View larger version (57K):
[in this window]
[in a new window]

  		FIGURE 2. FimH elicits an innate antiviral response in cells expressing TLR4. A, Peritoneal macrophages from B6 or TLR4–/– mice were treated with LPS, FimH, or poly(I:C) or left untreated and supernatants were assayed for TNF-{alpha} levels. B, Human lung fibroblasts (HEL; TLR4 negative), human foreskin fibroblasts (BJ; TLR4 positive) and murine B6 fibroblasts (B6 MEFs; TLR4 positive) were left untreated (control) or treated with poly(I:C), LPS, or FimH as indicated. Twenty-four hours posttreatment, cells were left uninfected (negative (–ve) control) or infected with VSV-GFP. GFP fluorescence was visualized 24 h postinfection.

 
FimH-induced innate immunity is not due to LPS or other bacterial contaminants

We next tested the levels of LPS in our column-purified recombinant FimH preparations using a standard Limulus amoebocyte lysate assay. The samples had very low LPS contamination, with 4–7 pg of LPS per µg of FimH protein. This level of LPS contamination would account for a maximum of 1.7 pg of LPS per 250 ng of FimH. Two hundred fifty ng/ml FimH demonstrates complete antiviral activity whereas 1 ng/ml LPS does not. To verify that contamination with LPS or other bacterial components is not responsible for the FimH activity, we produced preparations from bacteria that contained either the FimH-expressing plasmid or a control plasmid. Although samples with or without FimH were prepared in exactly the same manner and had similar levels of LPS, only FimH+ preparations provided antiviral protection in BJ fibroblasts (Fig. 3A) or B6 MEFs (data not shown) and induced TNF-{alpha} in peritoneal macrophages from B6 mice, but not TLR4–/– mice (Fig. 3B) or human PBMCs (data not shown). Moreover, enzymatic digestion or heat inactivation of FimH significantly abrogated its activity (Fig. 3C).


Figure 3
View larger version (24K):
[in this window]
[in a new window]

  		FIGURE 3. FimH-induced innate immunity is independent of LPS. The FimH protein purification protocol was performed using bacteria containing the FimH expression plasmid (FimH+ prep) or containing an empty vector (FimH– prep). LPS contamination levels were determined by Limulus amebocyte lysate assay. A, TLR4+ BJ fibroblasts were treated with either the FimH+ or FimH– preparation or left untreated (control). Twenty-four hours posttreatment, cells were left uninfected (–ve control) or infected with VSV-GFP. B, Peritoneal macrophages from B6 or TLR4–/– mice were treated with either the FimH+ or FimH– preparation and assayed for TNF-{alpha}. C, Intact, trypsin-digested, or heat-inactivated FimH was used to treat peritoneal macrophages from B6 or TLR4–/– mice and the levels of TNF-{alpha} were measured.

 
FimH signals via TLR4 in the absence of Md-2 and CD14 and binds directly to TLR4

TLR4 and MD-2 are indispensable for LPS responses (12, 13, 14, 15). To confirm that FimH signaling via TLR4 is independent of LPS signaling, we used the well established 293 cells stably transfected with either TLR4 alone (LPS unresponsive) or with TLR4 and MD-2/CD14 (LPS responsive). We first confirmed the expression of TLR4, Md-2, and CD14 (Fig. 4A). We then transiently transfected 293, 293/TLR-4, or 293/TLR-4/Md2/CD14 cells with a plasmid expressing luciferase from a TAT-like promoter fused to multiple copies of the NF-{kappa}B consensus sequence. FimH induced luciferase expression in both 293/hTLR4 and 293/hTLR4/Md-2/CD14 cells, whereas LPS only induced luciferase in 293/hTLR4/Md-2/CD14 cells (Fig. 4C). It is well known that LPS signaling induces the production of IL-8. To confirm that FimH can induce the production of IL-8 in the absence of LPS signaling, we measured the levels of IL-8 production in 293/hTLR4 cells. FimH was able to induce IL-8 production in the absence of Md-2 or CD14 (Fig. 4C). To determine whether FimH can directly bind TLR4, we performed an in vitro protein binding assay (Fig. 4D) using recombinant TLR4 fused to the Fc fragment of human IgG1 (TLR4-Fc; R&D Systems). A strong dose-dependent binding of immobilized FimH to TLR4 was observed. LPS, a known ligand for TLR4, was used as control. To confirm the specificity of FimH binding to TLR4, we used a control murine protein (IL-15Ra) that was fused to the human Fc fragment of IgG1 in the same manner as TLR4-Fc. No significant binding of FimH or LPS was detected with the control Fc protein (Fig. 4D).


Figure 4
View larger version (38K):
[in this window]
[in a new window]

  		FIGURE 4. FimH signals in cells unresponsive to LPS and directly interacts with TLR4. A, Total RNA was isolated from 293, 293-hTLR4, and 293-hTLR4-CD14-Md2 cells for RT-PCR (RT) analysis. B, 293, 293-hTLR4, and 293-hTLR4-CD14-Md2 cells were cotransfected with pCMV-βgal and pNF{kappa}B-luc. Sixteen hours later, cells were left untreated (Mock) or treated with FimH (2 µg/ml) or LPS (10 ng/ml). Six hours later, cells lysates were harvested and luciferase assays were performed. Luciferase levels were standardized to internal β-galactosidase levels as a transfection control and reported as fold increase relative to mock-treated controls for each cell line. The luciferase experiments were performed in triplicate three times. C, 293 and 293-hTLR4 cells were left untreated (mock) or treated with FimH (2 µg/ml) or LPS (10 ng/ml). Twenty-four hours posttreatment the supernatants were collected to measure the production of IL-8. D, FimH binding to TLR4 was assessed in an ELISA-like protein binding assay using a TLR4-Fc fusion protein. ELISA plates were coated with different concentrations (0.0625–8 µg/ml) of FimH or LPS. Immobilized FimH or LPS was then incubated with 2 µg/ml TLR4-Fc fusion protein. Specific TLR4 binding was measured through the Fc domain of the fusion protein using a HRP-conjugated anti-human IgG. Binding of immobilized FimH or LPS to IL-15R{alpha}-Fc was assayed similarly. Data shown are representative of three independent experiments.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
Bacteria encode many diverse PAMPs that serve as potent stimulators of the innate immune system. Adhesive pili, or fimbriae, are a defining feature of pathogenic bacteria. UPEC are able to express P, type 1, S, and F1C fimbriae. The type 1 fimbriae gene cluster contains 9 genes (FimA–FimI), of which four gene products, FimA, FimF, FimG, and FimH, form the fimbriae (16, 17). FimH is located at the tip and is involved in recognition by mannose. Recent crystal structure determination of FimH complexed with oligomannose-3 highlighted the feasibility of using natural and engineered mannose antagonists to block bacterial invasion and growth and biofilm formation (18). Previous studies using intact UPEC showed that both P and type 1 fimbriae signal through TLR4 to elicit chemokine production and neutrophil infiltration (6). In this study, we demonstrate that purified FimH protein is able to stimulate cytokine production through TLR4. These observations suggest that whereas UPEC use FimH to bind mannose on uroepithelial cell surfaces, the innate immune response is simultaneously recognizing FimH in a TLR4-dependent fashion. Absence of TLR4 on the host cells or FimH on the bacteria leads to significant reduction in the ability of UPEC to infect the urinary tract (data not shown).

The potent stimulatory activity of FimH is very unlikely to be due to contamination or synergy with LPS because of the following: 1) the amount of LPS required to induce an antiviral state in responsive cells was ~1000-fold higher than the levels of contaminating LPS in FimH preparations; 2) control preparations from bacteria not expressing FimH but processed identically to those expressing FimH had no stimulatory activity; 3) enzymatic digestion and heat inactivation of FimH significantly abrogated its activity; 4) the stimulatory activity of FimH was similar in LPS-responsive and -unresponsive cells, suggesting that FimH signals via TLR4 independently of MD-2; and 5) future purification of FimH by fast protein liquid chromatography, with no detectable LPS, had no effect on the potency of FimH activity (data not shown). Furthermore, whereas FimH has potent antiviral activity in an in vivo HSV-2 infection model, we detected no antiviral activity against high levels of LPS (data not shown).

The ability of the host to distinguish specific bacterial ligands, such as FimH, from common bacterial ligands, such as LPS, is critical to ensuring an effective host response to pathogenic organisms while maintaining tolerance to commensal organisms. Thus, it is not surprising that mucosal epithelial cells express TLR4 but not CD14, a coreceptor required for LPS recognition (19). As such, FimH serves as a potent stimulator of the innate immune response via interaction with TLR4 independently of LPS, allowing for recognition of pathogenic E. coli.


   Acknowledgments
 
We thank Dr. Shizuo Akira via Dr. Douglas Golenbock for breeding pairs of MyD88–/– mice.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
A patent for the use of FimH as an innate microbicide and antitumor agent has been filed.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by grants from Canadian Institutes of Health Research and the Hospital for Sick Children Foundation to A.A.A. and from Canadian Institutes of Health Research to K.L.M. Back

2 Address correspondence and reprint requests to Dr. Ali A. Ashkar, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada L8N 3Z5. E-mail address: ashkara{at}mcmaster.ca Back

3 Abbreviations used in this paper: PAMP, pathogen-associated molecular pattern; B6, C57BL/6; HEL, human embryonic fibroblast; hTLR4, human TLR4; MEF, murine embryonic fibroblast; poly(I:C), polyinosinic:polycitidylic acid; UPEC, uropathogenic E. coli; VSV, vesicular stomatitis virus. Back

Received for publication June 16, 2008. Accepted for publication September 19, 2008.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Kaisho, T., S. Akira. 2001. Toll-like receptors and their signaling mechanism in innate immunity. Acta Odontol. Scand. 59: 124-130. [Medline]
  2. Beutler, B.. 2004. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430: 257-263. [Medline]
  3. Klemm, P., M. Schembri, D. L. Hasty. 1996. The FimH protein of type 1 fimbriae. An adaptable adhesin. Adv. Exp. Med. Biol. 408: 193-195. [Medline]
  4. Meiland, R., S. E. Geerlings, S. Langermann, E. C. Brouwer, F. E. Coenjaerts, A. I. Hoepelman. 2004. Fimch antiserum inhibits the adherence of Escherichia coli to cells collected by voided urine specimens of diabetic women. J. Urol. 171: 1589-1593. [Medline]
  5. Connell, I., W. Agace, P. Klemm, M. Schembri, S. Marild, C. Svanborg. 1996. Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract. Proc. Natl. Acad. Sci. USA 93: 9827-9832. [Abstract/Free Full Text]
  6. Fischer, H., M. Yamamoto, S. Akira, B. Beutler, C. Svanborg. 2006. Mechanism of pathogen-specific TLR4 activation in the mucosa: fimbriae, recognition receptors and adaptor protein selection. Eur. J. Immunol. 36: 267-277. [Medline]
  7. Wizemann, T. M., J. E. Adamou, S. Langermann. 1999. Adhesins as targets for vaccine development. Emerg. Infect. Dis. 5: 395-403. [Medline]
  8. Kariyawasam, S., B. N. Wilkie, C. L. Gyles. 2004. Resistance of broiler chickens to Escherichia coli respiratory tract infection induced by passively transferred egg-yolk antibodies. Vet. Microbiol. 98: 273-284. [Medline]
  9. Paladino, P., D. T. Cummings, R. S. Noyce, K. L. Mossman. 2006. The IFN-independent response to virus particle entry provides a first line of antiviral defense that is independent of TLRs and retinoic acid-inducible gene I. J. Immunol. 177: 8008-8016. [Abstract/Free Full Text]
  10. Lee, J., S. Shin, C. H. Teng, S. J. Hong, K. S. Kim. 2005. FimH adhesin of Escherichia coli K1 type 1 fimbriae activates BV-2 microglia. Biochem. Biophys. Res. Commun. 334: 917-923. [Medline]
  11. Zhang, D., G. Zhang, M. S. Hayden, M. B. Greenblatt, C. Bussey, R. A. Flavell, S. Ghosh. 2004. A Toll-like receptor that prevents infection by uropathogenic bacteria. Science 303: 1522-1526. [Abstract/Free Full Text]
  12. Miyake, K., Y. Nagai, S. Akashi, M. Nagafuku, M. Ogata, A. Kosugi. 2002. Essential role of MD-2 in B-cell responses to lipopolysaccharide and Toll-like receptor 4 distribution. J. Endotoxin Res. 8: 449-452. [Medline]
  13. Nagai, Y., S. Akashi, M. Nagafuku, M. Ogata, Y. Iwakura, S. Akira, T. Kitamura, A. Kosugi, M. Kimoto, K. Miyake. 2002. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat. Immunol. 3: 667-672. [Medline]
  14. Shimazu, R., S. Akashi, H. Ogata, Y. Nagai, K. Fukudome, K. Miyake, M. Kimoto. 1999. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J. Exp. Med. 189: 1777-1782. [Abstract/Free Full Text]
  15. Kawasaki, K., H. Nogawa, M. Nishijima. 2003. Identification of mouse MD-2 residues important for forming the cell surface TLR4-MD-2 complex recognized by anti-TLR4-MD-2 antibodies, and for conferring LPS and Taxol responsiveness on mouse TLR4 by alanine-scanning mutagenesis. J. Immunol. 170: 413-420. [Abstract/Free Full Text]
  16. Jones, C. H., J. S. Pinkner, R. Roth, J. Heuser, A. V. Nicholes, S. N. Abraham, S. J. Hultgren. 1995. FimH adhesin of type 1 pili is assembled into a fibrillar tip structure in the Enterobacteriaceae. Proc. Natl. Acad. Sci. USA 92: 2081-2085. [Abstract/Free Full Text]
  17. Klemm, P., G. Christiansen. 1987. Three fim genes required for the regulation of length and mediation of adhesion of Escherichia coli type 1 fimbriae. Mol. Gen. Genet. 208: 439-445. [Medline]
  18. Wellens, A., C. Garofalo, H. Nguyen, N. Van Gerven, R. Slattegard, J. P. Hernalsteens, L. Wyns, S. Oscarson, H. De Greve, S. Hultgren, J. Bouckaert. 2008. Intervening with urinary tract infections using anti-adhesives based on the crystal structure of the FimH-oligomannose-3 complex. PLoS ONE 3: e2040
  19. Abreu, M. T., L. S. Thomas, E. T. Arnold, K. Lukasek, K. S. Michelsen, M. Arditi. 2003. TLR signaling at the intestinal epithelial interface. J. Endotoxin Res. 9: 322-330. [Medline]



This article has been cited by other articles:


Home page
 JEMHome page
F. A. Carvalho, N. Barnich, A. Sivignon, C. Darcha, C. H.F. Chan, C. P. Stanners, and A. Darfeuille-Michaud
Crohn's disease adherent-invasive Escherichia coli colonize and induce strong gut inflammation in transgenic mice expressing human CEACAM
J. Exp. Med., September 28, 2009; 206(10): 2179 - 2189.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mossman, K. L.
Right arrow Articles by Ashkar, A. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mossman, K. L.
Right arrow Articles by Ashkar, A. A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS